Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

T. J. Worgul, R. J. Santen, E. Samojlik, J. D. Veldhuis, Allan Lipton, Harold Harvey, J. R. Drago, T. J. Rohner

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, approximately 20 per cent of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1,000 mg. aminoglutethimide and 40 mg. hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project. One patient has had a complete response and is in remission after 275 weeks of therapy. A partial response was noted in 4 patients, while the disease was objectively stable in 6. Pre-treatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (p < 0.01). Response and drug toxicity are discussed.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalUnknown Journal
Volume129
Issue number1
DOIs
StatePublished - Jan 1 1983

Fingerprint

Aminoglutethimide
Carcinoma
Therapeutics
Prostatic Diseases
Hypophysectomy
Dihydrotestosterone
Adrenalectomy
Drug-Related Side Effects and Adverse Reactions
Disease Progression
Hydrocortisone
Testosterone
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Worgul, T. J. ; Santen, R. J. ; Samojlik, E. ; Veldhuis, J. D. ; Lipton, Allan ; Harvey, Harold ; Drago, J. R. ; Rohner, T. J. / Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. In: Unknown Journal. 1983 ; Vol. 129, No. 1. pp. 51-55.
@article{bd8c9180ee3440aa99e875c9f9eaacf9,
title = "Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma",
abstract = "Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, approximately 20 per cent of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1,000 mg. aminoglutethimide and 40 mg. hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project. One patient has had a complete response and is in remission after 275 weeks of therapy. A partial response was noted in 4 patients, while the disease was objectively stable in 6. Pre-treatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (p < 0.01). Response and drug toxicity are discussed.",
author = "Worgul, {T. J.} and Santen, {R. J.} and E. Samojlik and Veldhuis, {J. D.} and Allan Lipton and Harold Harvey and Drago, {J. R.} and Rohner, {T. J.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(17)51916-3",
language = "English (US)",
volume = "129",
pages = "51--55",
journal = "[No source information available]",
issn = "0042-1215",
number = "1",

}

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. / Worgul, T. J.; Santen, R. J.; Samojlik, E.; Veldhuis, J. D.; Lipton, Allan; Harvey, Harold; Drago, J. R.; Rohner, T. J.

In: Unknown Journal, Vol. 129, No. 1, 01.01.1983, p. 51-55.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

AU - Worgul, T. J.

AU - Santen, R. J.

AU - Samojlik, E.

AU - Veldhuis, J. D.

AU - Lipton, Allan

AU - Harvey, Harold

AU - Drago, J. R.

AU - Rohner, T. J.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, approximately 20 per cent of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1,000 mg. aminoglutethimide and 40 mg. hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project. One patient has had a complete response and is in remission after 275 weeks of therapy. A partial response was noted in 4 patients, while the disease was objectively stable in 6. Pre-treatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (p < 0.01). Response and drug toxicity are discussed.

AB - Treatment of male patients with advanced prostatic carcinoma and disease progression after initial endocrine therapy frequently is unsatisfactory. However, approximately 20 per cent of these patients respond to surgical adrenalectomy or hypophysectomy, indicating continued hormonal responsiveness. A total of 25 previously castrated men with stage D carcinoma received 1,000 mg. aminoglutethimide and 40 mg. hydrocortisone daily. The patients were evaluated using the criteria of the National Prostatic Cancer Project. One patient has had a complete response and is in remission after 275 weeks of therapy. A partial response was noted in 4 patients, while the disease was objectively stable in 6. Pre-treatment testosterone and dihydrotestosterone levels were measured in 9 of 25 patients and were significantly reduced statistically during aminoglutethimide therapy (p < 0.01). Response and drug toxicity are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0020659211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020659211&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(17)51916-3

DO - 10.1016/S0022-5347(17)51916-3

M3 - Article

VL - 129

SP - 51

EP - 55

JO - [No source information available]

JF - [No source information available]

SN - 0042-1215

IS - 1

ER -